CY1121038T1 - Θεραπεια καρκινου μαστου - Google Patents
Θεραπεια καρκινου μαστουInfo
- Publication number
- CY1121038T1 CY1121038T1 CY181101174T CY181101174T CY1121038T1 CY 1121038 T1 CY1121038 T1 CY 1121038T1 CY 181101174 T CY181101174 T CY 181101174T CY 181101174 T CY181101174 T CY 181101174T CY 1121038 T1 CY1121038 T1 CY 1121038T1
- Authority
- CY
- Cyprus
- Prior art keywords
- breast cancer
- cancer treatment
- compounds
- iii
- triple
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η αποκάλυψη περιγράφει τη χρήση μιας ή περισσοτέρων ενώσεων που εμπίπτουν εντός του σκοπού ενός ή περισσοτέρων από τους συντακτικούς τύπους I, II, III, IV, V ή VI για θεραπεία τριπλά αρνητικού καρκίνου μαστού. Ενώσεις που είναι χρήσιμες για τη θεραπεία καρκίνου μαστού περιλαμβάνουν αυτές τις ενώσεις των τύπων I, II, III, IV, V ή VI που παρεμποδίζουν πολλαπλασιασμό κυττάρων καρκίνου μαστού ή/και οδηγούν στο θάνατο κυττάρων καρκίνου μαστού, ιδιαιτέρως τριπλά αρνητικού καρκίνου μαστού.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161513361P | 2011-07-29 | 2011-07-29 | |
| PCT/US2012/048471 WO2013066440A1 (en) | 2011-07-29 | 2012-07-27 | Treatment of breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121038T1 true CY1121038T1 (el) | 2019-12-11 |
Family
ID=48192564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY181101174T CY1121038T1 (el) | 2011-07-29 | 2018-11-08 | Θεραπεια καρκινου μαστου |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9517229B2 (el) |
| EP (4) | EP3430907A1 (el) |
| JP (2) | JP6158180B2 (el) |
| KR (1) | KR101923250B1 (el) |
| CN (1) | CN103997894B (el) |
| BR (1) | BR112014002200A2 (el) |
| CA (1) | CA2843417C (el) |
| CY (1) | CY1121038T1 (el) |
| DK (1) | DK2739153T3 (el) |
| EA (1) | EA028452B1 (el) |
| ES (1) | ES2696074T3 (el) |
| HK (2) | HK1198867A1 (el) |
| HU (1) | HUE040524T2 (el) |
| MX (1) | MX359664B (el) |
| PL (1) | PL2739153T3 (el) |
| PT (1) | PT2739153T (el) |
| SI (1) | SI2739153T1 (el) |
| WO (1) | WO2013066440A1 (el) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA028452B1 (ru) * | 2011-07-29 | 2017-11-30 | Медивейшн Простейт Терапьютикс, Инк. | Лечение рака молочной железы |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| KR20220025231A (ko) | 2012-09-26 | 2022-03-03 | 아라곤 파마슈티컬스, 인코포레이티드 | 비전이성 거세 저항성 전립선암 치료용 항안드로겐 |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| KR102221005B1 (ko) | 2013-04-17 | 2021-02-26 | 시그날 파마소티칼 엘엘씨 | 전립선암 치료를 위한 디하이드로피라지노-피라진 화합물 및 안드로겐 수용체 길항제를 포함하는 조합 요법 |
| WO2015069266A1 (en) * | 2013-11-07 | 2015-05-14 | Flynn Daniel L | Methods for inhibiting tie2 kinase useful in the treatment of cancer |
| JP6945587B2 (ja) * | 2013-11-07 | 2021-10-06 | デシフェラ ファーマシューティカルズ，エルエルシー | ガンの処置に有用なｔｉｅ２キナーゼの阻害方法 |
| US10238630B2 (en) | 2014-05-28 | 2019-03-26 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer |
| MX2017007707A (es) | 2014-12-12 | 2018-03-06 | Medivation Prostate Therapeutics Llc | Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama. |
| CN107530283A (zh) | 2015-03-03 | 2018-01-02 | 奎尔波特股份有限公司 | 组合脂质体药物制剂 |
| CA2977397A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
| CN104857517B (zh) * | 2015-05-14 | 2018-04-27 | 南京海纳医药科技股份有限公司 | 一种恩杂鲁胺软胶囊及其制备方法 |
| US9963433B2 (en) * | 2016-01-29 | 2018-05-08 | Wayne State University | Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor |
| SG11201912403SA (en) | 2017-06-22 | 2020-01-30 | Celgene Corp | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
| KR20200070334A (ko) | 2017-10-16 | 2020-06-17 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
| CN107987055A (zh) * | 2017-12-19 | 2018-05-04 | 刘秀云 | 硫代咪唑二酮类雄激素受体拮抗剂及其用途 |
| SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
| US11292782B2 (en) | 2018-11-30 | 2022-04-05 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| BR112022002609A2 (pt) | 2019-08-12 | 2022-08-09 | Deciphera Pharmaceuticals Llc | Métodos de tratamento de tumores estromais gastrointestinais |
| KR20220123058A (ko) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물 |
| IL293866A (en) | 2019-12-30 | 2022-08-01 | Deciphera Pharmaceuticals Llc | Compositions of amorphous kinase inhibitors and methods of using them |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| DK2444085T3 (en) * | 2005-05-13 | 2015-04-27 | Univ California | Diarylhydantoinforbindelser as androgenreceptorantagonister for treating cancer |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| US20090299640A1 (en) | 2005-11-23 | 2009-12-03 | University Of Utah Research Foundation | Methods and Compositions Involving Intrinsic Genes |
| DK2656841T3 (en) * | 2006-03-27 | 2016-12-05 | Univ California | Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES |
| RU2449993C2 (ru) | 2006-03-29 | 2012-05-10 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Диарилтиогидантоиновые соединения |
| CA2966280A1 (en) | 2007-10-26 | 2009-04-30 | The Regents Of The University Of California | Diarylhydantoin compounds |
| US8450290B2 (en) * | 2007-11-26 | 2013-05-28 | Enzon Pharmaceuticals, Inc. | Methods for treating androgen receptor dependent disorders including cancers |
| WO2009114534A1 (en) | 2008-03-14 | 2009-09-17 | The Regents Of The University Of California | Multi-gene classifiers and prognostic indicators for cancers |
| ES2457534T3 (es) | 2008-05-30 | 2014-04-28 | The University Of North Carolina At Chapel Hill | Perfiles de expresión génica para predecir desenlaces en cáncer de mama |
| RU2548918C2 (ru) | 2009-02-24 | 2015-04-20 | Медивэйшн Простейт Терапьютикс, Инк. | Специфические соединения диарилгидантоина и диарилтиогидантоина |
| EP2416657A4 (en) | 2009-04-09 | 2012-09-05 | Medivation Prostate Therapeutics Inc | COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF |
| WO2011022316A1 (en) | 2009-08-20 | 2011-02-24 | The Regents Of The University Of Colorado, A Body Corporate | Mirnas dysregulated in triple-negative breast cancer |
| WO2011044327A1 (en) * | 2009-10-07 | 2011-04-14 | Medivation Prostate Therapeutics, Inc. | Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds |
| US9066963B2 (en) | 2011-03-15 | 2015-06-30 | The University Of North Carolina At Chapel Hill | Methods of treating breast cancer with anthracycline therapy |
| EA028452B1 (ru) * | 2011-07-29 | 2017-11-30 | Медивейшн Простейт Терапьютикс, Инк. | Лечение рака молочной железы |
| CA2857505A1 (en) | 2011-11-30 | 2013-06-06 | The University Of North Carolina At Chapel Hill | Methods of treating breast cancer with taxane therapy |
| CA2882621A1 (en) | 2012-08-23 | 2014-02-27 | The Regents Of The University Of Colorado, A Body Corporate | Method for determining breast cancer treatment |
| AR092982A1 (es) | 2012-10-11 | 2015-05-13 | Isis Pharmaceuticals Inc | Modulacion de la expresion de receptores androgenicos |
| US20140154681A1 (en) | 2012-11-12 | 2014-06-05 | Nanostring Technologies, Inc. | Methods to Predict Breast Cancer Outcome |
| US10679730B2 (en) | 2013-05-28 | 2020-06-09 | The University Of Chicago | Prognostic and predictive breast cancer signature |
| MX2017007707A (es) | 2014-12-12 | 2018-03-06 | Medivation Prostate Therapeutics Llc | Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama. |
-
2012
- 2012-07-27 EA EA201400178A patent/EA028452B1/ru not_active IP Right Cessation
- 2012-07-27 PT PT12846720T patent/PT2739153T/pt unknown
- 2012-07-27 EP EP18190012.7A patent/EP3430907A1/en not_active Withdrawn
- 2012-07-27 EP EP19187649.9A patent/EP3610731A1/en not_active Withdrawn
- 2012-07-27 SI SI201231453T patent/SI2739153T1/sl unknown
- 2012-07-27 MX MX2014001218A patent/MX359664B/es active IP Right Grant
- 2012-07-27 DK DK12846720.6T patent/DK2739153T3/en active
- 2012-07-27 EP EP12846720.6A patent/EP2739153B1/en active Active
- 2012-07-27 EP EP20191500.6A patent/EP3791724A1/en not_active Withdrawn
- 2012-07-27 BR BR112014002200A patent/BR112014002200A2/pt not_active Application Discontinuation
- 2012-07-27 HU HUE12846720A patent/HUE040524T2/hu unknown
- 2012-07-27 KR KR1020147005617A patent/KR101923250B1/ko active IP Right Grant
- 2012-07-27 US US14/236,036 patent/US9517229B2/en active Active
- 2012-07-27 JP JP2014523048A patent/JP6158180B2/ja active Active
- 2012-07-27 PL PL12846720T patent/PL2739153T3/pl unknown
- 2012-07-27 CN CN201280048192.2A patent/CN103997894B/zh active Active
- 2012-07-27 WO PCT/US2012/048471 patent/WO2013066440A1/en active Application Filing
- 2012-07-27 ES ES12846720T patent/ES2696074T3/es active Active
- 2012-07-27 CA CA2843417A patent/CA2843417C/en active Active
-
2014
- 2014-12-10 HK HK14112422.7A patent/HK1198867A1/xx unknown
-
2015
- 2015-02-11 HK HK15101529.1A patent/HK1201413A1/xx unknown
-
2016
- 2016-12-09 US US15/373,914 patent/US10111861B2/en active Active
-
2017
- 2017-03-31 JP JP2017072819A patent/JP2017141269A/ja active Pending
-
2018
- 2018-10-24 US US16/168,896 patent/US20190262315A1/en not_active Abandoned
- 2018-11-08 CY CY181101174T patent/CY1121038T1/el unknown
-
2020
- 2020-01-22 US US16/749,133 patent/US20210069154A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121038T1 (el) | Θεραπεια καρκινου μαστου | |
| CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
| CY1119387T1 (el) | Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου | |
| CY1121450T1 (el) | Θεραπεια συνδυασμου για θεραπεια καρκινου | |
| CL2015003395A1 (es) | Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad | |
| SMT201600132B (it) | Derivati fosforammidati di 5-fluoro-2'-desossiuridina per uso nel trattamento del cancro | |
| UY34566A (es) | 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| UY32882A (es) | (heteroarilmetil) tiohidantoínas sustituidas | |
| MX2015014234A (es) | Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1. | |
| UY34278A (es) | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| PH12015501576A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| EA201590987A1 (ru) | Соединения и способы их применения | |
| NI201500051A (es) | Modulación de la expresión de receptores androgénicos | |
| MA40076A (fr) | Inhibiteurs de syk | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer | |
| EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
| CL2016000150A1 (es) | Compuestos y composiciones como inhibidores de la mek | |
| PH12015501088A1 (en) | Dimeric compounds | |
| NI201300112A (es) | Composición que comprende aflibercept, ácido folínico, 5 - fluorouracilo (5 - fu) e irinotecano ( folfiri). | |
| CO7111292A2 (es) | Derivados cíclicos de diaminopirimidina | |
| EA201300610A1 (ru) | Хиназолинкарбоксамидазетидины |